One year after launching the myLIFTINGroller and a new LED mask model, myBlend is expanding its skin-care-focused beauty tech ecosystem with two new handheld devices: myBLEMISHpen and myDARKSPOTpen, developed in connection with Nuon Médical.

The two pens carry forward a strategy of targeted, single-concern devices rather than multi-use platforms. myBLEMISHpen addresses skin imperfections using blue light, while myDARKSPOTpen targets pigmentation spots with green light. Both devices draw on dermatological protocols, according to the brand, pairing blue light with additional light-based action in the case of the blemish pen.

The timing matters for professional buyers. myBlend built its line around the myLIFTINGroller and an updated LED mask, both launched roughly twelve months ago. Adding two SKUs within a year signals a faster cadence for the brand's device pipeline and a deliberate move into the acne- and pigment-correction segment, where at-home light therapy competes directly with in-clinic protocols.

For treatment providers and retailers, the split approach — one device per indication — has procurement implications. Clinics and spas that already stock the mask or roller can position the pens as entry-price add-ons for clients managing breakouts or dark spots between visits, rather than replacing higher-intensity in-office equipment. The blue light blemish pen maps onto the same mechanism dermatologists use for mild-to-moderate acne, and the green light pen addresses melanin-related discoloration, a concern that typically drives repeat purchase in the 35-plus demographic.

The Nuon Médical connection also signals the medical-device manufacturing angle. Partnering with a medtech player gives myBlend a compliance and credibility anchor for light-based claims, which matters as regulators and advertising authorities in the EU scrutinize at-home device efficacy statements more closely.

Watch the next data point: whether myBlend publishes clinical or instrumental efficacy studies for the two pens, which would determine how far claims can stretch in EU marketing channels.